Nautilus Biotechnology, Inc. Common Stock NAUT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:49:29.596Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:40:14.822866151Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:49:29.144568+00:00
Nautilus Biotechnology, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.06 | 180.7% | 22.0% | |||
| 25Δ | 2.15 | 174.4% | 19.5% | |||
| 30Δ | 2.24 | 168.0% | 16.9% | |||
| 35Δ | 2.34 | 161.7% | 14.3% | |||
| 40Δ | 2.43 | 155.4% | 11.7% | |||
| 45Δ | 2.59 | 159.4% | 9.6% | |||
| 50Δ | 2.95 | 196.4% | 9.0% | |||
| 55Δ | 3.31 | 233.4% | 8.4% | |||
| 60Δ | 2.28 | 167.6% | 4.9% | 3.68 | 270.4% | 7.9% |
| 65Δ | 2.04 | 252.4% | 4.7% | 4.04 | 307.4% | 7.3% |
| 70Δ | 1.80 | 337.2% | 4.5% | 4.41 | 344.3% | 6.7% |
| 75Δ | 1.56 | 422.0% | 4.2% | 4.77 | 381.3% | 6.1% |
| 80Δ | 1.32 | 506.8% | 4.0% | 5.76 | 435.5% | 5.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.06
- IV
- 180.7%
- B/E move
- 22.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.15
- IV
- 174.4%
- B/E move
- 19.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.24
- IV
- 168.0%
- B/E move
- 16.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.34
- IV
- 161.7%
- B/E move
- 14.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.43
- IV
- 155.4%
- B/E move
- 11.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.59
- IV
- 159.4%
- B/E move
- 9.6%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.95
- IV
- 196.4%
- B/E move
- 9.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.31
- IV
- 233.4%
- B/E move
- 8.4%
60Δ
- Pseudo strike
- 2.28
- IV
- 167.6%
- B/E move
- 4.9%
- Pseudo strike
- 3.68
- IV
- 270.4%
- B/E move
- 7.9%
65Δ
- Pseudo strike
- 2.04
- IV
- 252.4%
- B/E move
- 4.7%
- Pseudo strike
- 4.04
- IV
- 307.4%
- B/E move
- 7.3%
70Δ
- Pseudo strike
- 1.80
- IV
- 337.2%
- B/E move
- 4.5%
- Pseudo strike
- 4.41
- IV
- 344.3%
- B/E move
- 6.7%
75Δ
- Pseudo strike
- 1.56
- IV
- 422.0%
- B/E move
- 4.2%
- Pseudo strike
- 4.77
- IV
- 381.3%
- B/E move
- 6.1%
80Δ
- Pseudo strike
- 1.32
- IV
- 506.8%
- B/E move
- 4.0%
- Pseudo strike
- 5.76
- IV
- 435.5%
- B/E move
- 5.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 184.48% | |
| 148.09% |
Biotechnology
NBTX
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
More →NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →NRIX
Description unavailable
More →